Group items matching
in title, tags, annotations or url
Imiquimod cream (Aldara) for superficial basal cell carcinoma: NPS - better choices, better health - 0 views
Treatment of Cutaneous Tumors with Topical 5% Imiquimod Cream | Alessi SS, et al | CLINICS 2009;64(10):961-6 - 0 views
-
-
For patients without comorbidities, our study revealed good cure rates for superficial BCC and superficial/nodular BCC (88% and 85%, respectively). Nodular and aggressive BCC and Bowen's disease exhibited lower cure rates (50%, 50%, and 57%, respectively). I
-
-
For patients without comorbidities, our study revealed good cure rates for superficial BCC and superficial/nodular BCC (88% and 85%, respectively). Nodular and aggressive BCC and Bowen's disease exhibited lower cure rates (50%, 50%, and 57%, respectively). I
Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study in Europe | European Journal of Dermatology | 2005 - 0 views
-
The initial sBCC clearance rate was 90% (12-week post treatment), whereas the proportion of subjects who were clinically clear at 2 years (current time point) was estimated to be 79.4%.
Superficial basal cell carcinoma treated with imiquimod 5% topical cream for a 4-week period: a case series. [J Eur Acad Dermatol Venereol. 2009] - PubMed - 0 views
-
Clinical clearance rate at 1 and 2 years were 89% and 85%, respectively.
Aldara (tm) [imiquimod] Cream ~ Full Prescribing Information ~ FDA / Package Insert - 0 views
-
FDA-approval: * Biopsy-confirmed, primary superficial basal cell carcinoma (sBCC) in immunocompetent adults; maximum tumor diameter of 2.0 cm on trunk, neck, or extremities (excluding hands and feet), only when surgical methods are medically less appropriate and patient follow-up can be reasonably assured (1.2)
Treatment of Cutaneous Tumors with Topical 5% Imiquimod Cream - 0 views
-
For patients without comorbidities, our study revealed good cure rates for superficial BCC and superficial/nodular BCC (88% and 85%, respectively). Nodular and aggressive BCC and Bowen's disease exhibited lower cure rates (50%, 50%, and 57%, respectively). I
Efficacy of Aldara® (Imiquimod) for Treatment of Low-Risk Nodular Basal Cell Carcinoma Defined - 0 views
-
Aldara® can eradicate 64% of low-risk nodular basal cell carcinomas.
Recurrence rate of superficial basal cell carcinom... [Eur J Dermatol. 2008 Nov-Dec] - PubMed result - 0 views
-
The estimate of overall treatment success for all treated patients at the end of follow-up was 77.9% (80.9% considering histology). The data support clinical assessment of initial response as predictive of long-term outcome. Most of the recurrences occurred early, indicating that careful follow-up is important during the first year after treatment.
Management of superficial basal cell carcinoma: fo... [Clin Cosmet Investig Dermatol. 2009] - PubMed result - 0 views
-
To date one long-term study indicates a treatment success rate of 78%-81% and that initial response is a predictor of long-term outcome. Recurrences tend to occur within the first year after treatment. Future research will compare this preparation to the gold standard treatment for superficial BCC - surgical excision.
Recurrence rate of superficial basal cell carcinom... [Eur J Dermatol. 2005 Sep-Oct] - PubMed result - 0 views
-
The initial sBCC clearance rate was 90% (12-week post treatment), whereas the proportion of subjects who were clinically clear at 2 years (current time point) was estimated to be 79.4%.
‹ Previous
21 - 40 of 52
Next ›
Showing 20▼ items per page